Summary of patient preference for different treatment profiles
| Treatment profile I | Treatment profile II | Treatment profile III | ||
| Attribute levels | Risk of fatigue as a side effect of treatment | 15% | 25% | 35% |
| Risk of falls or fracture as a side effect of treatment | 3% | 20% | 10% | |
| Risk of cognitive impairment as a side effect of treatment | 0% | 5% | 5% | |
| Risk of hypertension as a side effect of treatment | 5% | 25% | 15% | |
| Extension of time until cancer-related pain occurs | 15 months | 35 months | 35 months | |
| Risk of rashes as a side effect of treatment | 5% | 25% | 15% | |
| CRPC | Summed preference weights: mean (95% CI) | 3.234 (2.905 to 3.563) | −2.088 (–2.296 to –1.880) | −0.062 (–0.149 to 0.026) |
| Patients in favour of the profile: N (%) | 128 (93.4%) | 2 (1.5%) | 7 (5.1%) | |
| mCRPC | Summed preference weights: mean (95% CI) | 3.226 (2.776 to 3.675) | −2.141 (–2.420 to –1.861) | −0.151 (–0.268 to –0.034) |
| Patients in favour of the profile: N (%) | 72 (93.5%) | 1 (1.3%) | 4 (5.2%) | |
| nmCRPC | Summed preference weights: mean (95% CI) | 3.245 (2.758 to 3.732) | −2.020 (−2.334 to –1.706) | 0.053 (–0.073 to 0.179) |
| Patients in favour of the profile: N (%) | 56 (93.3%) | 1 (1.7%) | 3 (5%) |
CRPC, castration-resistant prostate cancer; mCRPC, metastatic CRPC ; nmCRPC, non-metastatic CRPC.